Courtney Flaherty

Articles

Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial

April 4th 2024

Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.

Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant Ovarian Cancer

April 4th 2024

Debra L. Richardson, MD, FACS, FACOG, expands on results with upifitamab rilsodotin in platinum-resistant high-grade serous ovarian cancer.

FDA Grants Rare Pediatric Disease Designation to LSTA1 in Osteosarcoma

March 29th 2024

LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.

Ponatinib Plus Chemo Records Several ‘Firsts’ in Ph+ ALL and Becomes New SOC

March 29th 2024

Elias Jabbour, MD, expands on the significance of ponatinib’s approval in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

March 28th 2024

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Experts Discuss Current Standards, Selection, and Uncertainties in Bladder and Renal Cancer Care

March 27th 2024

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.

Capivasertib/Fulvestrant Wins Approval in Japan for Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

March 27th 2024

Capivasertib plus fulvestrant has been approved in Japan for pretreated, PIK3CA-, AKT1-, or PTEN-altered, HR-positive, HER2-negative breast cancer.

First-Line Osimertinib Plus Chemo Demonstrates Consistent Benefit in EGFR-Mutant NSCLC

March 26th 2024

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.

Luspatercept Provides Effective First-Line Alternative to ESAs in Lower-Risk MDS

March 26th 2024

Sunil Iyer, MD, expands on the impact of the FDA’s approval of luspatercept on the management of lower-risk myelodysplastic syndrome.

A Groundbreaking First in CLL/SLL: Liso-Cel Makes its Mark as Only CAR T-Cell Therapy Approved

March 25th 2024

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC

March 25th 2024

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

First-Line Nivolumab/Ipilimumab Combo Meets OS End Point in Advanced HCC

March 20th 2024

Improved overall survival was achieved with nivolumab plus ipilimumab vs standard-of-care TKIs in patients with advanced hepatocellular carcinoma.

Ixabepilone Plus Bevacizumab Generates Survival Benefit and Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 19th 2024

Ixabepilone plus bevacizumab produced a survival advantage and high response rates vs ixabepilone alone in platinum-resistant ovarian cancer.

FDA Grants Fast Track Designation to MVR-T3011 for Pretreated Recurrent/Metastatic HNSCC

March 19th 2024

The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.

Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care

March 18th 2024

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology

March 18th 2024

Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.

Navigating Career Crossroads: Insights from Hope Rugo’s Journey as a Woman in Oncology

March 15th 2024

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

Pembrolizumab Plus Concurrent CRT Meets OS End Point in High-Risk, Locally Advanced Cervical Cancer

March 15th 2024

The KEYNOTE-A18 trial met its coprimary end point of improved OS with pembrolizumab plus concurrent chemoradiotherapy in high-risk cervical cancer.

FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R/R Multiple Myeloma

March 14th 2024

P-BCMA-ALLO1 has been granted orphan drug designation by the FDA for the treatment of patients with relapsed/refractory multiple myeloma.

Perioperative Tislelizumab Shows Marked Benefit in Both Squamous and Nonsquamous Resectable NSCLC

March 13th 2024

Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.